AzA may serve as a potential endogenous biomarker for the assessment of the function of OATP1B3-P-gp for the prediction of changes in the pharmacokinetics of drugs transported by OATP1B3 -P-gp in liver disease states. Here, SLCO1B3 is linked to liver disorder.